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Abstract
Neo-blood vessel growth (angiogenesis), which may involve the activation of pre-existing endothelial cells (EC) and/or the
recruitment of bone marrow-derived vascular precursor cells (BM-VPC), is essential for tumor growth. Molecularly, besides
the well established roles for Vascular endothelial growth factor (VEGF), recent findings show the Notch signalling pathway,
in particular the ligand Delta-like 4 (Dll4), is also essential for adequate tumor angiogenesis; Dll4 inhibition results in
impaired, non-functional, angiogenesis and reduced tumor growth. However, the role of BM-VPC in the setting of Notch
pathway modulation was not addressed and is the subject of the present report. Here we show that SDF-1 and VEGF, which
are produced by tumors, increase Dll4 expression on recruited BM-VPC. Mechanistically, BM-VPC activated, in a Dll4-
dependent manner, a transcriptional program on mature EC suggestive of EC activation and stabilization. BM-VPC induced
ICAM-2 and Fibronectin expression on EC, an effect that was blocked by a Dll4-specific neutralizing antibody. In vivo,
transplantation of BM-VPC with decreased Dll4 into tumor-bearing mice resulted in the formation of microvessels with
decreased pericyte coverage and reduced fibronectin expression. Consequently, transplantation of BM-VPC with decreased
Dll4 resulted in impaired tumor angiogenesis, increased tumor hypoxia and apoptosis, and decreased tumor growth. Taken
together, our data suggests that Dll4 expression by BM-VPC affects their communication with tumor vessel endothelial cells,
thereby modulating tumor angiogenesis by affecting vascular stability.
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Introduction
Besides sprouting of pre-existing endothelium, tumor angiogenesis
may require also the contribution of bone marrow-derived endothelial
progenitor cells (EPC) [1], previously shown to be recruited into tumors
(reviewed in [2]) and proven essential for tumor angiogenesis [3].
However, the mechanisms by which EPC contribute towards
angiogenesis still remain largely undisclosed, mainly because of the
very low number of EPC found within tumor biopsies, in or around
vessels [4,5]. Moreover, the identity of true ‘‘EPC’’ with proangiogenic
functions is still under intense scrutiny (Reviewed in [6]). For instance,
recent reports have elegantly shown that bone marrow-derived
myelomonocytic cells but not ‘‘EPC’’ have proangiogenic potential
during spontaneous tumor formation and growth [7]. Therefore, bone
marrow-derived cells other than pure ‘‘EPC’’ may also play a crucial
role during tumor angiogenesis and growth; a more detailed molecular
and functional definition of EPC and of other bone marrow-derived
cells with proangiogenic potential is clearly needed.
Notch signalling is crucial during embryonic development, for the
differentiation of different tissues, and also in adult homeostasis.
Notch ligands (Delta like 4, Dll4) and receptors (Notch 1 and Notch
4) have been shown to be involved in the differentiation and
function of the vasculature, during embryogenesis and in adults. In
detail, Dll4 deficient mice have severe vascular defects, similar to
Notch 1 and 4 knock-outs [8,9]. More strikingly, in inbred genetic
backgrounds Dll4 heterozygous embryos (in haploinsufficiency) die
at mid gestation due to severe vascular effects, highlighting its
importance in vasculogenesis and its role over other members of the
Notch pathway [10,11]. Notably, similar vascular defects are
observed in haploinsufficient VEGF mouse embryos [12]. Conse-
quently, a putative role for Dll4 in tumor angiogenesis has been
under intense scrutiny [13,14,15,16]. However, it is still unclear
whether Dll4 is only expressed on tumor vessels or other cell types,
and what role it plays during angiogenesis.
Given its crucial role in modulating vessel formation and
function, in the present study, we hypothesized Dll4 expressed on
bone marrow derived vascular progenitor cells (BM-VPC) might
play a role in tumor angiogenesis, either by activating the pre-
existing endothelium or by promoting vessel stabilization following
sprouting and proliferation.
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Results
SDF1 and VEGF induce Dll4 expression on BM-VPC
BM-VPC have been shown to be recruited into the peripheral
blood in response to VEGF and SDF1 produced by tumors and to
express Notch signalling pathway components, such as Dll4 [17].
We investigated whether these factors were able to regulate the
expression of Dll4 on BM-VPC.
BM-VPC were cultured in presence of VEGF or SDF1 for
18 hours. Dll4 expression was analysed by RQ-PCR and flow-
cytometry. Dll4 expression was significantly increased on BM-
VPC cultured in presence of both VEGF and SDF1 compared to
the control condition (Figure 1A), although comparatively SDF1
induced a greater increase in Dll4 expression. We also verified that
Dll4 regulation by SDF1 was mediated via its receptor, CXCR4.
We incubated BM-VPC with SDF1 alone or in the presence of a
CXCR4 inhibitor for 18 h and analysed the cells by flowcyto-
metry. As shown in Figure 1B, CXCR4i prevents DLL4 induction
by SDF1 (Figure 1B). The results show that the expression of Dll4
on BM-VPC is induced by VEGF and by SDF1; the latter effect is
mediated through its receptor, CXCR4.
Dll4 induces a vascular activation and stabilization
program on mature EC in vitro
We hypothesized that DLL4, driven by BM-VPC, could signal
on EC, inducing molecular changes that may lead to an
angiogenic response in vitro and in vivo. To test this hypothesis,
we cultured HUVEC together with BM-VPC isolated from mDll4
overexpression (mDll4GOF BM-VPC) or heterozygous (low
expression) Dll4+/2 (Dll4+/-BM-VPC) mice and used HUVEC
co-cultured with WT BM-VPC as control. After o.n. contact, we
removed BM-VPC and compared HUVEC gene expression using
a microarray containing 113 genes related to EC biology. In
particular, the expression of ICAM2, FN1 and VE-Cadherin
increased in HUVEC cultured in presence of mDll4GOF BM-
VPC and decreased in case of Dll4+/2 BM-VPC (Figure 2A).
To further demonstrate that the regulation of these genes on EC
was Dll4-specific we co-cultured HUVEC and mouse BM-VPC, in
presence or absence of a mouse Dll4-specific inhibitor antibody
(mDll4i). Hey2 and Hes1 quantification was used to confirm the
activation state of the Notch signaling pathway on HUVEC. As
shown in Fig. 2B, Dll4 inhibition on BM-VPC decreased Hey2 but
not Hes1 expression by co-cultured HUVEC; in contrast, the
gamma-secretase and Notch signaling inhibitor, GSI, inhibited both
downstream Notch target genes (Figure 2B). Quantitative Q-PCR
was used to determine the differences in the expression of ICAM2,
FN1 and VE-Cadherin, in co-cultured HUVEC. Notably, FN1 and
ICAM2 expression on induced by BM-VPC on HUVEC decreased
in the presence of the Dll4 inhibitor (n = 3, P,0,05)(Fig. 2c). In
contrast, VE-Cadherin expression was not altered by Dll4 inhibition
(Figure 2C). Inversely, when HUVEC were co-cultured with
mDll4GOF BM-VPC, the expression of FN1 and ICAM2
decreased, while VE-Cadherin was not altered (Figure 2D). Taken
together, these in vitro data indicate that Notch signaling pathway
activation of EC by Dll4 driven by BM-VPC induces gene
expression changes on EC, namely of genes linked to endothelial
activation and stability such as fibronectin and ICAM2.
Dll4 expression by BM-VPC is essential for tumor
angiogenesis and growth
Next, to test whether the role of Dll4-expressing BM-VPC was
essential to tumor angiogenesis, we developed an in vivo approach in
which we reconstituted NOD-SCID mice BM with BM-VPC obtained
from Dll4+/2 (heterozygous, with reduced Dll4 levels) or from WT
(normal Dll4 levels) mice. As shown by fluorescent in situ hybridization
using a Y chromosome probe, WT BM-PC and Dll4+/2 BM-VPC
engraft the bone marrow of irradiated recipient mice, are recruited into
the peripheral blood 2 weeks after tumor implant and incorporate the
tumor mass at approximately the same rates and frequency (Figure 3)
Normal BM-VPC (male lin-flk1+) or from Dll4+/2 mice
(Dll4+/2 BM-VPC) were used in transplantation experiments
into recipient female mice. Next, we analysed tumor angiogenesis
using a well established in vivo model of human chloroma (solid
leukemia-derived tumor, previously shown to be very efficient at
recruiting BM-VPC, [2]). Tumor microvessel density was
determined by immunofluorescence staining against PE-CAM.
As seen in Figure 4, Human tumors growing in mice transplanted
with Dll4+/2 BM-VPC had a significantly higher microvessel
density than those with BM-VPC-WT.
However, if tumors were allowed to grow beyond 15 days, there
was a significant growth delay of tumors in BM-VPC-Dll4+/2
Figure 1. Dll4 expression on BM-VPC is induced by VEGF and SDF1. A. Expression of Dll4 in BM-VPC was detected by RT-PCR. B. BM-VPC
were incubated with SDF1 (50 ng/ml) or SDF1 and CXCR4 inhibitor (5 ug/ml) The number of Dll4 positive cells was quantified by flow cytometry
using anti-Dll4 mouse specific. Each experiment was performed in triplicate and the mean represented n = 3. (values show the mean plus s.e.m.
*: P,0.05).
doi:10.1371/journal.pone.0018323.g001
Dll4 on EPC and Angiogenesis
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Figure 2. Dll4 expressed on BM-VPC stimulate a vascular activation and stabilization program on endothelial cells. A. Genes
differently expressed on HUVEC after co-cultered with BM-VPC-WT, BM-VPC-Dll4 or mDll4GOF BM-VPC. These results were obtained from one
hybridization using pooled samples from 3 experiments. B. Expression of Hey2 and Hes1 in HUVEC co-cultured with mouse isolated BM-VPC in
presence of mouse specific neutralizing antibody for Dll4 (mDll4i) or c-secretase inhibitor (cSi). C. ICAM2, FN1 and VE-Cadherin expression in HUVEC
co-cultured with mouse BM-VPC or BM-VPC in presence of mouse specific neutralizing antibody for Dll4 (mDll4i). D. ICAM2, FN1 and VE-Cadherin
expression in HUVEC co-cultured with mouse BM-VPC-WT or MDll4GOF BM-VPC. Gene expression was quantified by RT-PCR in B,C and D. (values
show the mean plus s.e.m. *: P,0.05).
doi:10.1371/journal.pone.0018323.g002
Dll4 on EPC and Angiogenesis
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transplanted versus control mice or those with WT BM-VPC
(Figure 5A). As determined by Tunel (to identify apoptotic cells)
and phospho-histone H3 (which identifies proliferating cells)
staining, tumors with Dll4+/2 BM-VPC showed significantly a
higher apoptosis index and lower proliferation rate than control
and WT BM-VPC (Figure 5B–C).
Dll4 expression by BM-VPC affects the stability of tumor
vessels
We assessed vessel stability as determined by immunofluores-
cence staining against fibronectin (FN1) and SMA (smooth muscle
actin, which identifies pericytes). We observed that tumors with
Dll4+/2 BM-VPC had significantly lower FN1 content
(Figure 6A) in the vessels and these had significantly less pericyte
coverage, suggesting these would likely be more unstable (the
PECAM/SMA ratio of the tumors is shown in Figure 6B; the
higher the ratio the less pericyte/SMA coverage of tumor vessels).
Moreover, as determined by staining tumor frozen sections with
hypoxiprobe (which labels hypoxic tumor areas), tumors with
Dll4+/2 BM-VPC had significantly greater proportion of hypoxic
areas, which strongly suggests that the vessels in these tumors were
less functional (Figure 6C). Taken together, these data show the
tumor vessels grown in BM Dll4+/2 BM-VPC transplanted
versus control mice or those with BM-VPC-WT are non-
functional, leaky vessels.
Dll4 expression on BM-VPC affects vessel stability in late
stages of tumor growth
Having shown the relevance of Dll4 expression on BM-VPC for
EC behavior in vitro, next we investigated whether these effects
were also observed in vivo during tumor growth and specifically
dependent on Dll4 expression by BM-VPC using a xenograft
tumor model of mouse breast carcinoma (HTH-k). For that we
increased the number of circulating BM-VPC by administering
mouse BM-VPC derived from Dll4GOF mice with induced Dll4
over-expression (mDll4GOF BM-VPC) or normal Dll4 expression
(WT BM-VPC) after tumor establishment during a restricted
period of time. We analysed subcutaneous tumor xenografts of
mice injected at day 6, 8 and 10 with BM-VPC, compared with
mice in the same experimental conditions but without BM-VPC
administration (Figure 7).
To assess vessel stability we quantified Fibronectin 1 content in
blood vessels of controls, WT BM-VPC and mDll4GOF BM-VPC
tumors. We identified endothelial cells by immunostaining with
PE-CAM. To assess vessel stability we quantified Fibronectin 1
content and blood vessel diameter in blood vessels of tumors.
Fibronectin 1 expression and vessel diameter were significantly
higher in tumors treated with mDll4GOF BM-VPC than WT
BM-VPC (Figure 7A–7C). However, the vessel density and tumor
Figure 3. BM-VPC-Dll4 engraft bone-marrow of NOD-SCID mice
and are recruited to peripheral blood during tumour growth.
BM-VPC-WT and BM-VPC-Dll4 are equally present in bone-marrow and
peripheral blood 15 days after inoculation of cells. BM-VPC were
identified using FISH to Y chromosome.
doi:10.1371/journal.pone.0018323.g003
Figure 4. Dll4+/-BM-VPC increase tumour vessel density in tumors. Endothelial cells were identified by immunofluorescence using anti-CD31
(PE-CAM) in tumor cryosections from mice inoculated with BM-VPC-WT or BM-VPC-Dll4. Scale Bar indicates 250 mm. Graphs show the number of
microvessels per section (values show the mean plus s.e.m. *: P,0.05).
doi:10.1371/journal.pone.0018323.g004
Dll4 on EPC and Angiogenesis
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volume (data not shown) were similar between controls, WT BM-
VPC and mDll4GOF BM-VPC tumors (Figure 7D). Taken
together, this data suggest that specific expression of Dll4 on BM-
VPC modulates vessel morphology at tumor site, increasing
fibronectin1 content.
Discussion
Therapeutic approaches to target tumor angiogenesis have
shown promising pre-clinical results [18,19,20], although some
studies have reported significant side effects, while others have
suggested better and more detailed molecular studies are still
needed given the relatively modest therapeutic benefits observed
[21,22]. It is now well established that VEGF is not the only factor
essential for tumor angiogenesis, and that other signalling
pathways play a crucial role during the initial (sprouting) and
the late (stabilization) phases of this intricate and complex process.
Moreover, the role for, and the importance of, the endogenous
(pre-existing) and the ‘‘external’’ (BM-recruited progenitors,
termed VPC throughout this manuscript) factors that regulate
endothelial cells during tumor angiogenesis is still largely
undisclosed and has been the theme of some controversy.
Recent studies revealed that the Notch signalling pathway, and
specifically its ligand Dll4, is crucial for adequate tumor
angiogenesis [15,23,24]. In detail it was shown that therapeutic
strategies aimed at neutralizing Dll4 binding to its receptor (with
Dll4 neutralizing antibodies) resulted in inefficient angiogenesis
due to vessel instability. A putative role for BM-VPC in the setting
of Notch:Dll4 signaling during tumor angiogenesis has not been
studied and was the subject of the present report.
Our results demonstrate that BM-VPC are activated during
tumor growth by SDF1 and VEGF resulting in increased Dll4
expression. VEGF and SDF1 produced in the tumor microenvi-
ronment, and released systemically, have been implicated in BM-
VPC recruitment and retention in perivascular sites [25]. In this
paper, we demonstrate that these cytokines are also responsible for
the activation of BM-VPC. It has already been described that
SDF1 increases BM-VPC-dependent vasculogenesis [26]. How-
ever, the molecular mechanism responsible for this effect was
unknown. Here we show that SDF1 is able to regulated Dll4
expression in BM-VPC altering the angiogenic response. There-
fore, the Dll4 expression levels might be considered as a general
marker for vascular responses, such as during tumor angiogenesis
or vascular remodelling events.
Dll4 expression on EC activates the Notch signalling pathway
resulting in the regulation of tumor angiogenesis in a VEGF-
independent manner [23,24,27]. In the present paper, we show
that BM-VPC also regulates Notch signalling activity on EC via
Dll4 expression. Dll4 expressed by BM-VPC was able to regulate
FN1 and ICAM2 (among other genes) expression on mature EC,
suggesting it might modulate vessel stability and activation
programs. As already described in the context of the Dll4
overexpression mutant, Notch signalling activation by Dll4 on
EC was able to regulate the expression of several components of
the extracellular matrix including FN1 [28], suggesting it
modulates vessel stability by controlling the expression of ECM
components of the basement membrane. Moreover, it was already
shown that the overexpression of Dll4 on EC increases the
expression of VE-cadherin, a cell-to-cell adhesion molecule [28].
Our results do not show any difference in endothelial cell VE-
Figure 5. Dll4+/2BM-VPC tumors have a smaller growth rate than WT BM-VPC tumors, and increased apoptosis. A. Tumor volume
((LxW2)/2) in control, WT BM-VPC and Dll4+/2 BM-VPC-Dll4 tumors. B. As determined by TUNEL staining, tumor apoptosis index 15 days after
inoculation, in control, WT BM-VPC and Dll4+/2 BM-VPC tumors. C. Tumor proliferation index (number of phosphor-histone 3 (pH3) per section) pH 3
staining in tumor cryosections. These quantifications were done in triplicate, in tumor sections obtained from 2 independent experiments. Scale bar
indicates 150 mm. (values show the mean plus s.e.m. *: P,0.05).
doi:10.1371/journal.pone.0018323.g005
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cadherin expression with our without Dll4 inhibition on BM-VPC.
This might indicate that VE-Cadherin regulation on endothelial
cells is a cell-autonomous mechanism, since in our experiments
Notch activation by Dll4 expressed on EC was not tested. Besides
promoting leukocyte adhesion during inflammatory responses,
ICAM2 is also implicated in angiogenesis, where it was shown to
promote tube formation [29]. Taken together, Dll4 expression on
BM-VPC is able to activate mature EC, which strongly suggests
the cross-talk between these 2 cell types is crucial for adequate
tumor angiogenesis.
In vivo, we observed that reduction of Dll4 expression on BM-
VPC, and subsequent transplantation into tumor bearing mice,
decreased tumor vessel stabilization resulting in the formation of
unstable vessels. Dll4 reduction on BM-VPC (Dll4+/2 BM-VPC)
and their transplantation into tumor-bearing mice resulted in the
formation of unstable vessels, as evidenced by the reduced pericyte
coverage, reduced Fibronectin expression; this led to appearance
of more hypoxic areas and consequently decreased tumor growth.
Vessel instability has been previously observed in other studies
looking at the importance of Dll4 during tumor angiogenesis and
also embryonic vasculogenesis [23,24,27], but this effect was not
related to the contribution/involvement of BM-VPC. In addition,
we also demonstrate that specifically modulating Dll4 expression
on BM-VPC is sufficient to affect vascular stability of tumor vessels
during a restricted period throughout tumor development.
Globally, the results presented here show that gene expression
alterations in the ligand Dll4 on BM-VPC regulate angiogenesis at
the tumor site. Nevertheless, we cannot exclude the possible
Figure 6. Dll4+/-BM-VPC regulates vessel stability in tumors. A. FN1 expression was detected by immunofluorescence (FN1) endothelial cells
were stained using anti-PE-CAM antibody. B. Quantification of the number of PE-CAM+SMA+ and PE-CAM+SMA- vessels, (PECAM/SMA ratio of
2.260.9 versus 4.662.3, respectively, * P,0.05). Scale Bar represents 350 mm. C. Hypoxia index 15 days after inoculation (number of hipoxyprobe
positive cells per section) (* P,0.05). Scale bars represent 350 mm.These quantifications were done in triplicate, in tumors from 2 independent
experiments.
doi:10.1371/journal.pone.0018323.g006
Dll4 on EPC and Angiogenesis
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contribution/involvement of other Notch ligands in the commu-
nication between BM-VPC and resident tumor endothelial cells.
Taken together, our data further supports the concept that Dll4
expression and Notch signalling pathway activation must be tightly
controlled to produce a normal and functional vessel network. Our
data shows that BM-VPC may be essential in the control of this
signalling pathway at different stages of tumor angiogenesis. Dll4
expression by BM-VPC may therefore be considered as an
important regulator of vessel stabilization, essential for tumor
angiogenesis but also in other vascular pathologies.
Materials and Methods
Mouse strains
Dll4 +/2 mutant mice are kept on a CD1 outbred background.
Dll4GOF mice are heterozigous double mutants for TetO7-Dll4
[28] and Tie2-rtTA-M2 [30], in C57/BL6 background. Trans-
gene induction was performed 5 days before BM recovery, by
adding doxycycline (4 mg/ml) (Sigma-Aldrich) in drinking water
containing 4% sucrose (Sigma-Aldrich), ad libitum delivery.
Mouse BM-VPC isolation
We obtained BM cells and isolated Lin- cells (which are negative
for the following markers CD5, CD45R(B220), CD11b, Gr-1 (Ly-
6G/C), 7-4, and Ter-119) using magnetic sorting (Miltenyi Biotec-
MACS). For in vitro experiments, Lin- cells were isolated from
balbC, Dll4+/2, Dll4GOF and respective WT counterparts. For in
vivo experiments Lin- cells from Dll4+/2 mice and corresponding
WT counterparts were then sorted by FACS for Flk1 expression (PE
conjugated Flk1 antibody from Pharmingen). Lin-Flk1+ cells (96–
99% purity, as determined by FACS sorting) were defined as BM-
VPC-WT or Dll4+/2 BM-VPC and were injected intravenously
(16104 cells per injection) into mice without further culture.
To determine Dll4 induction by VEGF and SDF1, we cultured
BM Lin- cells isolated from BalbC mice (with 4 to 6 weeks of age)
in RPMI medium (Gibco) without any supplements in presence of
VEGF (20 ng/ml, Sigma-Aldrich) and Heparin (5 U/ml, Sigma-
Aldrich) or SDF1 (50 ng/ml, R and D Systems). To inhibit SDF1
activation we incubated BM-VPC with SDF1 and CXCR4
antagonist (5 mg/ml AMD3100, Sigma-Aldrich).
In vitro co-culture assays
HUVEC were cultured at 16104/cm2 cell density using EBM2
supplemented medium (Lonza) with 5% FBS (foetal bovine serum,
Sigma-Aldrich), in 0,2% gelatine (Sigma-Aldrich) coated plates.
After 24 h, medium was change to EBM2 supplemented medium
(Lonza) with 2% FBS (foetal bovine serum, Sigma-Aldrich) and
16105 mBM-VPC from Dll4+/2, Dll4GOF and respective WT,
were put over cultured HUVEC monolayer. Cell contact was
maintained for 18 h. After this period mBM-VPC were washed
from the cultures and HUVECs collected for mRNA extraction.
Neutralizing antibodies anti-mDll4 were added to co-cultures at
50 ug/ml (kindly provided by Dr. Hideo Yagita). The cultures
using mDll4GOF BM-VPC and respective controls were main-
tained in presence of doxycyclin (1 mg/ml) (Sigma-Aldrich) for
transgene induction.
Figure 7. Increased expression of Dll4 in circulating blood cells regulates vessel stability in early stages of tumor development.
A. Fibronectin 1 (FN1) and PECAM expression were detected by immunofluorescence. Scale bar indicates 50 mm B. FN1 staining quantification was
performed using ImageJ. C. Vessel diameter was quantified measuring the smallest distance between two endothelial nuclei in opposing sides at
more than 4 different vessel levels. D. Vessel density was obtained by counting the number of vessels per section. (values show the mean plus s.e.m.
*: P,0.05).
doi:10.1371/journal.pone.0018323.g007
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Endothelial cell biology microarray
We used Oligo GEArrays HybTube Format from SABiosciences.
Total mRNA was isolated from HUVEC obtained from co-culture
experiments with BM-VPC-Dll4+/2, MDll4GOF BM-VPC and
respective WT counterparts. mRNA was obtained from 3 indepen-
dent experiments and pooled together in similar proportions. cDNA
synthetisis and array hybridization was performed as recommended
by manufacturer instructions.
Gene expression by RQ-PCR
mRNA levels were measured by real time RQ-PCR on the ABI
PrismH 7900HT Sequence Detection System (Applied Biosystems)
using the following primers and probes: hHey2 hHes1 Fibronectin1
VE-Cadherin hICAM2, mDll4. The housekeeping gene used to
normalize the samples was 18S (human18S rRNA - 20x, Applied
Biosystems) or ß-actin (agccatgtacgtagccatcc; ctctcagctgtggtggtgaa)
(mouse). Each sample was analyzed in triplicate and each PCR
experiment included at least one non-template control well.
Membrane arrays were analysed using ImageJ.
In vivo tumor formation assays
We performed two types of in vivo assays, one reconstituting
mouse bone marrow with mBM-VPC with altered expression of
Dll4 and the other introducing exogenous human progenitor cells
expressing Dll4. In the first case, we used female NOD-SCID mice
as recipients. NOD-SCID mice were sublethally irradiated (200
rads) and were intravenously injected after 24 hours with BM-
VPC-WT or BM-VP C-dll4+/2 (n = 6 in each experiment, for
each condition). Control mice were not injected with BM-VPC.
After three days, controls, BM-VPC-WT and BM-VPC-dll4+/2
reconstituted mice were subcutaneously injected with 66106
Human HL60 cell line (myeloid leukemia, which forms chloro-
mas). Tumor volume was determined at different time points. The
mice were sacrificed 15 days or 25 days after tumor implantation
and blood samples were collected. Tumors were frozen and fixed
for subsequent analysis. In the second in vivo assay, we used
NOD-SCID mice that were subcutaneously injected with 46106
mouse breast cancer cell line (HTH-K, [31,32]). After 6 days, we
divided the tumor injected mice into three groups, no cell
treatment (n = 4), WT BM-VPC treated mice (n = 4) and
mDll4GOF BM-VPC treated mice (n = 4). BM-VPC (36105 cells
per injection) were administered intravenously (obtained from
mDll4GOF mice bone-marrow by Ficoll density gradient
centrifugation and isolated as Lin- population; see BM-VPC
isolation) at day 6, 8 and 10 after tumor inoculation. Mice were
killed at day 11 after tumor inoculation.
Fluorescent in situ hybridization (FISH)
Fixed blood samples and frozen BM sections were used. Frozen
sections were rehydrated in PBS, then hybridized with a specific
probe for mouse Y chromosome (Cambrio, UK). Frozen sections
and blood samples were denaturation at 85uC for 5 minutes.
Hybridization was carried out at 37uC overnight.
Tumor microvessel determination, TUNEL, Proliferation,
Hypoxia
Tumours cryosections were blocked with a 5% FBS/0,1% BSA
solution in PBS for 30 minutes. Slides were then covered with
primary antibodies (rat anti-PECAM from Pharmingen), mouse
anti-alpha-SMA (DAKO) or rabbit anti-Histone 3 (Chemicon)
overnight at 4uC. After 3 brief washes in PBS, secondary
antibodies from Invitrogen (anti-rat-FITC, anti-mouse-Alexa568,
anti-rabbit-Alexa488, respectively) and incubated for 2 hours. For
the quantification of stable (CD31+ and SMA+) versus unstable
(CD31+SMA-) vessels, stained sections were visualized, and the
total number of vessels was determined in 5 high power fields
(x400 magnification). For hypoxia determination we used
Hypoxyprobe kit (Chemicon) and performed the immunostaining
as indicated by the manufacturer. After briefly washing the slides
in PBS, the slides were mounted in fluorescence mounting
medium from DAKO. Slides were photographed using a standard
fluorescence microscope. Hypoxia tumor area was determined by
visualizing stained sections and quantifying the number of stained/
unstained cells in 5 high power fields (x400 magnification).
Statistical Analysis
Differences in tumor growth, proliferation, apoptosis, hypoxia
and stable versus unstable vessels were analysed by ANOVA.
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